Australian Cancer Drug Shows Promise to Cure With Few Side Effects

© Flickr / Derek K. MillerVenetoclax promises to cure cancer
Venetoclax promises to cure cancer - Sputnik International
Tests on Venetoclax, a drug developed in Melbourne, have demonstrated that nearly four out of five patients showed positive results without side-effects. The drug has recently been approved for use in certain conditions in the United States and the European Union.

Venetoclax development began in 1988 after scientists at the Walter and Eliza Hall Institute of Medical Research (WEHI) discovered that cancer cells survived for longer periods of time due to the presence of a BCL-2 protein.

"Cells, when they are born, are destined to die and cancer cells, and particularly leukaemia cells, delay that death by using a protein called BCL-2, that stops the normal time of death," Professor John Seymour, of the Peter MacCallum Cancer Centre told 7.30. "Venetoclax blocks the action of BCL-2 so that cancer cells die in a usual way."

Along with four out of five patients who showed positive results, one had a complete remission. As Robert Oblak, one of the patients with chronic lymphocytic leukaemia, said to 7.30, the drug caused no side-effects. Oblak stated that within a year his leukaemia went into remission.

Some patients had negative results, but, according to Professor Andrew Roberts, a clinical haematologist and WEHI's head of clinical translation, Venetoclax saw positive responses in almost 80 percent of the 116 participants.

Cancer cells may be shifted to a state where they can be treated - Sputnik International
Brit Teen Claims to Invent New Treatment for Deadly Breast Cancer
There have been several cancer-research breakthroughs recently. Immunotherapy, a promising area of study, incorporates the immune system to kill cancer cells, and has worked in treating melanoma.

Manufacturer AbbVie has applied to the Therapeutic Goods Administration for approval to use Venetoclax more widely.

Meanwhile, patients on the trial continue to be treated. Researchers are looking for possible advances in areas of rarer cancers, as mesothelioma, pancreatic, liver and brain cancers have not shown the same level of improvement after using the drug.

To participate in the discussion
log in or register
Заголовок открываемого материала